C-ETLXFission Pharma
DRP1-FIS1 inhibitors, small molecules, mitochondrial protection
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-ETLX
C-ETLXC-ETLXDRP1-FIS1 inhibitors, small molecules, mitochondrial protection
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Fission Pharma DRP1-FIS1 inhibitors, small molecules, mitochondrial protection
Fission Pharma is creating drug-like small molecule mimetics of P110, a mito-protective peptide originating from Stanford University. The company is targeting DRP1-FIS1 mediated mitochondrial damage downstream of inflammation, with potential applications in neurodegenerative and age-related diseases including ALS, HD, AD, ischemic heart disease, and other degenerative conditions. Its planned pipeline includes CNS compounds, peripheral compounds, and tissue-restricted compounds.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Fission Pharma — Early mechanism · Bottom quartile. Derived deterministically from 7 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (6 programs at preclinical).…
Source: Deterministic